Association of endothelial and red blood cell microparticles with acute myocardial infarction in Chinese: a retrospective study

Abstract

Background: Mounting evidence suggests that endothelial cell-derived microparticles (EMPs) and red blood cell-derived microparticles (RMPs), which have procoagulant and vasoconstriction effects, are involved in the development of vascular acute cardiovascular events. The aim of this study was to analyze the circulating levels of EMPs and RMPs in patients with acute myocardial infarction (AMI), and to explore the correlations between EMPs and RMPs and the severity of coronary artery disease.Methods: Plasma samples from 110 patients with AMI and 57 non-coronary artery disease group (non-CAD) were collected in the present study. The flow cytometry was used to measure the EMPs (CD31) and RMPs (CD235a) qualitatively and quantitatively.Results: The levels of EMPs and RMPs in the AMI group were higher than that in the Non-CAD group, yet no significant difference was found between STEMI and non-STEMI subjects. The levels of EMPs and RMPs in multi-vessel were higher than in the single-vessel l disease. In the Thrombolysis in Myocardial Infarction (TIMI) risk assessment, the levels of EMPs in the high-risk group were higher than that in both intermediate-and low-risk group. The low-risk group had the lowest EMP levels, the difference between the groups being statistically significant (P=0.001). No significant difference in RMP levels was noted upon TIMI stratification. According to the ROC curve analysis, the areas under the curve (AUC) of EMPs and RMPs were 0.706 and 0.668, respectively. Conclusions:The circulating levels of EMPs and RMPs in patients with AMI are elevated, and the level of EMPs is related to the degree of coronary artery disease and the prognosis risk. The EMPs are more likely to be potential biomarkers than RMPs to provide diagnostic value for AMI.

Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review

“…In addition, in malignant diseases, there is a link between TF+MPs and the recurrence of VTE [ 54 ]. Furthermore, RMPs and EMPs have been regarded as putative agents in the development of coronary heart disease and vascular events, e.g., acute myocardial infarction, whereas GMPs and other WBCs-derived MPs interact with immune cells and enhance the production of pro-inflammatory cytokines, participating in the pathogenesis and evolution of cardiovascular and allergic disorders, infections, pre-eclampsia or cancer [ 55 , 56 ]. Overall, we may hypothesize that MPs and CECs can be employed as diagnostic tools in MPNs, to differentiate between MPNs subtypes and secondary causes of polycythemia, thrombocytosis or myelofibrosis, and also to predict the occurrence of vascular events.…”

Proteomics analysis of coronary blood microparticles in patients with acute myocardial infarction

“…Considering the clinical differences between AMI patients and SCAD patients, which are mainly related to the pathophysiology of the acute and stable states, SCAD patients were selected as the control group. Our team’s previous research found that MPs play extremely important roles in the occurrence and development of CVD [ 14 ]. Therefore, in this study, a proteomic analysis was performed of the MPs from the coronary blood of patients with AMI.…”

“…Zacharia et al [ 13 ] found that MPs increase inflammation and thrombosis in acute coronary syndrome (ACS) patients, and their concentration is positively correlated with the degree of coronary artery stenosis in ACS patients. A previous study revealed elevated levels of EMPs in AMI patients, and EMP levels are associated with the degree of coronary artery disease and prognostic risk [ 14 ].…”

Red Blood Cell-Derived Extracellular Vesicles: An Overview of Current Research Progress, Challenges, and Opportunities

“…Yuan et al revealed increased levels of RBC EVs in Chinese individuals with acute myocardial infarction compared to those with non-coronary artery disease. However, no significant difference in RBC EV levels was observed in Thrombolysis in Myocardial Infarction (TIMI) risk stratification [69]. Giannopoulos et al reported that STEMI patients treated with primary percutaneous coronary intervention (PCI) had increased levels of RBC EVs (twice that of healthy volunteers).…”